We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Female Health FHCO
An SI Board Since November 2010
Posts SubjectMarks Bans Symbol
204 6 0 VERU
Emcee:  Savant Type:  Unmoderated
Makers of the female condom. Was FHCO, now VERU also with cancer drugs in development
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
204Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of Savant-May 8
203Veru to Present at the GLP-1 Based Therapeutics Summit MIAMI, FL, May 02,Savant-May 2
202Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and SeSavant-April 30
201VERU quite the move since Feb 14....up 300+% Of course, that's after a majoSavant-April 11
200Veru Reschedules Annual Meeting of Shareholders --Restated historical finSavant-March 22
199Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor Savant-March 12
198Veru Announces Notification from Nasdaq Related to Delayed Quarterly ReporSavant-March 12
197Veru Announces New Scientific Advisory Board for its Enobosarm Program for Savant-February 20
196Veru Submits IND Application to FDA for the Development of Enobosarm to PrSavant-January 8
195Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partneSavant-10/16/2023
194Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm,Savant-9/11/2023
193Veru Reports Fiscal 2023 Third Quarter Financial Results Company receives Savant-8/10/2023
192Veru Inc.'s Oncology Drug Research Program Partner, The University of TSavant-6/21/2023
191Second Quarter Financial Summary: Fiscal 2023 vs Fiscal 2022 -- Net revenuSavant-5/15/2023
190 Agreement reached with FDA on confirmatory Phase 3 clinical trial designSavant-5/11/2023
189Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 FemalSavant-4/19/2023
188Veru Announces Preclinical Results from Expanded Sabizabulin Program into InflueSavant-4/11/2023
187Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits PSavant-4/11/2023
186VERU filed a $200 mln shelf offeringSavant-3/20/2023
185Veru Inc. said Tuesday it may be forced to delay, reduce or eliminate cliniSavant-3/14/2023
184Share of Veru Inc. (VERU) plunged 31.0% toward a 2 1/2-year low in premarkeSavant-3/3/2023
183Investigation Alert GRNC, VERU, GPS, UIS: Johnson Fistel, LLP Encourages LoSavant-2/24/2023
182Veru Reports Fiscal 2023 First Quarter Financial Results (
181Veru Inc. (VERU) estimates and forecastsVeru Inc. share prices are performing paSavant-2/6/2023
180VERU CC Feb 9, 8 am estSavant-1/26/2023
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):